Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aquestive Therapeutics, Inc. (AQST)

Aquestive Q3 revenue falls 41% to $7.6 million; net loss widens to $16.5 million

Negative Impact 3 of 5 earnings Written later

Aquestive reported third-quarter 2026 revenue of $7.6 million, down 41% from $12.8 million a year earlier, mainly due to the timing of Suboxone product orders. Its net loss widened to $16.5 million, or $0.13 per share, from $15.4 million, or $0.14 per share, while the company said its full-year 2026 guidance is unchanged. Shareholders face a weaker quarter, with the FDA decision on Anaphylm, due March 16, 2027, still ahead.

Key points

  • Q3 2026 total revenue was $7.6 million, down from $12.8 million in Q3 2025.
  • Net loss was $16.5 million, or $0.13 per share, versus $15.4 million, or $0.14 per share, a year earlier.
  • Non-GAAP adjusted EBITDA loss was $12.2 million, compared with $8.6 million in Q3 2025.
  • Full-year 2026 total revenue guidance of $46 million to $50 million was unchanged; cash and cash equivalents were $90.3 million at September 30, 2026.

The filing

CompanyAquestive Therapeutics, Inc. (AQST)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:15 PM ET
Accession number0001398733-26-000073

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.